ACLS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dimitrov, N.
Right arrow Articles by Cantell, K
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dimitrov, N.
Right arrow Articles by Cantell, K
Annals of Clinical and Laboratory Science, Vol 14, Issue 1, 32-39
Copyright © 1984 by Association of Clinical Scientists

Articles

Interferon as a modifier of estrogen receptors

NV Dimitrov, CJ Meyer, H Strander, S Einhorn, and K Cantell

Interferon (IFN-alpha) increased estrogen receptor (ER) activity in human breast cancer tissue, human uterus (endometrium), and rabbit uterus. The optimum response was obtained with three different doses of IFN-alpha 10, 100, and 1000 U per ml. Escalation of the dose up to 5000 U per ml did not increase further ER activity. Cytosol fractions with zero or low binding activity (below 10 fm per mg) did not respond to IFN-alpha treatment. Addition of antibodies against IFN-alpha resulted in abrogation of IFN-alpha effect. Use of recombinant IFN-alpha or highly purified lymphoblastoid IFN-alpha showed similar effects on ER. The mechanism of the augmentation effect of ER activity by IFN-alpha is not clear. The increase of ER activity may have important clinical applications if the same is obtained in vivo.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1984 by the Association of Clinical Scientists.